Skip to content

Trial Summary

A phase 2 trial of nivolumab plus ipilimumab, ipilimumab alone, or cabazitaxel in men with metastatic castration-resistant prostate cancer

Acronym:

Checkmate 650

ACTRN/NCT /ethics:

NCT02985957

Scientific title:

Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer

Sponsor / Cooperative group:

Bristal-Myers Squibb

Trial & Patient Characteristics

Cancer TypeProstate
Trial TypeTreatment
PhasePhase II
Age Range18+ years
SexMale
Tumour StreamProstate cancer
Cancer StageMetastatic or Widespread
Anticipated Start Date2017-03-17
Anticipated End Date2022-05-30

Participating Hospitals

HospitalLyell McEwin Hospital
Clinical Trial CoordinatorAndy Phay
Emailandy.phay@sa.gov.au
Phone08 8282 0833
Principal InvestigatorDr Christopher Hocking
Recruitment StatusRecruiting